Cullinan Therapeutics, Inc. (CGEM) analyst actions
Rating and price-target actions on CGEM in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the CGEM overview →
1 measured CGEM analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program | Press release | +0.47% | +5.08% |
Keep exploring
More CGEM: earnings → · SEC filings → · CGEM overview →